(Reuters) - Martin Shkreli, the former drug company executive who drew public outcry when he raised the price of a life-saving drug by 5,000 percent, will be tried for securities fraud separately from a lawyer charged alongside him, a Brooklyn federal judge ruled Wednesday.
Read more
No comments:
Post a Comment